echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The first general-purpose CAR-T in China was approved for clinical use from Beiheng Bio

    The first general-purpose CAR-T in China was approved for clinical use from Beiheng Bio

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 17, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration showed that the CTA101 UCAR-T cell injection product independently developed by Nanjing Beiheng Biotechnology Co.


    Acute lymphoblastic leukemia is a type of malignant proliferative tumor originating from precursor B or T lymphoid precursor cells in the bone marrow, blood, and extramedullary


    CTA101 is a CTA101 cell injection independently developed by Beiheng Biological with independent intellectual property rights


    It is reported that CTA101 adopts the "off-the-shelf" CAR-T cell therapy developed by Beiheng Bio's general CAR-T technology platform.


    It is reported that the results of the CTA101 exploratory clinical study (IIT) were published in April 2021 in the form of the original paper of Clinical Cancer Research


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.